Evidence map›Paper›PMID 28708811›Full record

Observational studyJournal of acquired immune deficiency syndromes (1999)2017

Challenges in Translating PrEP Interest Into Uptake in an Observational Study of Young Black MSM.

Charlotte-Paige Rolle, Eli S Rosenberg, Aaron J Siegler, Travis H Sanchez, Nicole Luisi, Kevin Weiss, Scott Cutro, Carlos Del Rio, Patrick S Sullivan, Colleen F Kelley

Abstract readObservational Study
In one paragraph

Observational study in Journal of acquired immune deficiency syndromes (1999), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Charlotte-Paige Rolle*Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA; †Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA; ‡Department of Infectious Diseases, Kaiser Permanente, Atlanta GA; and §Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA.
Eli S Rosenberg
Aaron J Siegler
Travis H Sanchez
Nicole Luisi
Kevin Weiss
Scott Cutro
Carlos Del Rio
Patrick S Sullivan
Colleen F Kelley

Funding

Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
Emory HIV/AIDS Clinical Trials UnitUM1AI069418 · NIAID · EMORY UNIVERSITY · PI Moises Arturo Huaman Joo, Colleen F Kelley · 2012 to 2026
$46.0M
Understanding substance use and incident HIV/STI among young black MSMR01DA038196 · NIDA · EMORY UNIVERSITY · PI ROSENBERG, ELI SAMUEL, SULLIVAN, PATRICK SEAN · 2014 to 2018
$3.2M
Defining the rectal mucosa in MSM at risk of HIV infectionK23AI108335 · NIAID · EMORY UNIVERSITY · PI KELLEY, COLLEEN F · 2013 to 2017
$855k
NIAID NIH HHS K23 AI108335NIAID NIH HHS P30 AI050409NIAID NIH HHS UM1 AI069418NIDA NIH HHS R01 DA038196
6 · The paper itself

Abstract

backgroundHIV incidence among US young, black men who have sex with men (YBMSM) is high, and structural barriers (eg lack of health insurance) may limit access to Pre-exposure prophylaxis (PrEP). Research studies conducted with YBMSM must ensure access to the best available HIV prevention methods, including PrEP.

methodsWe implemented an optional, nonincentivized PrEP program in addition to the standard HIV prevention services in a prospective, observational cohort of HIV-negative YBMSM in Atlanta, GA. Provider visits and laboratory costs were covered; participant insurance plans and/or the manufacturer assistance program were used to obtain drugs. Factors associated with PrEP initiation were assessed with prevalence ratios and time to PrEP initiation with Kaplan-Meier methods.

resultsOf 192 enrolled YBMSM, 4% were taking PrEP at study entry. Of 184 eligible men, 63% indicated interest in initiating PrEP, 10% reported no PrEP interest, and 27% wanted to discuss PrEP again at a future study visit. Of 116 interested men, 46% have not attended a PrEP initiation appointment. Sixty-three men (63/184; 34%) initiated PrEP; 11/63 (17%) subsequently discontinued PrEP. The only factor associated with PrEP initiation was reported sexually transmitted infection in the previous year (prevalence ratio 1.50, 95% confidence interval: 1.002 to 2.25). Among interested men, median time to PrEP initiation was 16 weeks (95% confidence interval: 7 to 36).

conclusionsDespite high levels of interest, PrEP uptake may be suboptimal among YBMSM in our cohort even with amelioration of structural barriers that can limit use. PrEP implementation as the standard of HIV prevention care in observational studies is feasible; however, further research is needed to optimize uptake for YBMSM.

Indexed as

AdultAnti-HIV AgentsBlack or African AmericanCohort StudiesHIV InfectionsHIV SeronegativityHomosexuality, MaleHumansMalePatient Acceptance of Health CarePre-Exposure ProphylaxisProspective StudiesRisk FactorsUnited StatesYoung AdultAnti-HIV Agents

Identifiers

PMID28708811
PMCPMC5634925

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.